GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Return-on-Tangible-Asset

NextGen Biomed (XTAE:NXGN) Return-on-Tangible-Asset : -34.06% (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. NextGen Biomed's annualized Net Income for the quarter that ended in Jun. 2023 was ₪-4.18 Mil. NextGen Biomed's average total tangible assets for the quarter that ended in Jun. 2023 was ₪12.28 Mil. Therefore, NextGen Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was -34.06%.

The historical rank and industry rank for NextGen Biomed's Return-on-Tangible-Asset or its related term are showing as below:

XTAE:NXGN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -149.29   Med: -42.72   Max: -20.69
Current: -68.65

During the past 9 years, NextGen Biomed's highest Return-on-Tangible-Asset was -20.69%. The lowest was -149.29%. And the median was -42.72%.

XTAE:NXGN's Return-on-Tangible-Asset is ranked worse than
82.09% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: -2.685 vs XTAE:NXGN: -68.65

NextGen Biomed Return-on-Tangible-Asset Historical Data

The historical data trend for NextGen Biomed's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Return-on-Tangible-Asset Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only -33.85 -48.07 -25.28 -20.69 -57.78

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.43 -11.88 -21.32 -98.30 -34.06

Competitive Comparison of NextGen Biomed's Return-on-Tangible-Asset

For the Medical Instruments & Supplies subindustry, NextGen Biomed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's Return-on-Tangible-Asset falls into.



NextGen Biomed Return-on-Tangible-Asset Calculation

NextGen Biomed's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-8.572/( (16.333+13.336)/ 2 )
=-8.572/14.8345
=-57.78 %

NextGen Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-4.182/( (13.336+11.219)/ 2 )
=-4.182/12.2775
=-34.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2023) net income data.


NextGen Biomed  (XTAE:NXGN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


NextGen Biomed Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.